


## Newly-identified compound inhibits SARS-CoV-2 by targeting the nucleocapsid protein

July 10 2023



N-17 is a potential inhibitor of SARS-CoV-2 nucleocapsid protein, shows nanomolar activity against the HCoV-OC43 and SARS-CoV-2 viruses and may prevent SARS-CoV-2 replication and transcription by blocking the packaging process of viral RNA. Credit: *Acta Materia Medica* (2023). DOI: 10.15212/AMM-2023-0021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has



spread globally since 2020. The nucleocapsid (N) protein plays a crucial role in the life cycle of SARS-CoV-2.

The authors of an article published in *Acta Materia Medica* have established a method to screen inhibitors of N protein by using microscale thermophoresis assays to obtain potential anti-SARS-CoV-2 agents. 1,7-bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one (N-17, a diphenylheptane) was identified as a compound with outstanding inhibitory activity.

The binding of N-17 to the N-terminal domain of N protein (N-NTD) was further validated by using drug affinity responsive target stability assays. The ability of N-17 to bind N protein was evaluated and the affinity of N-17 to the N-NTD with molecular docking and molecular dynamics simulation was predicted.

N-17 exhibited excellent anti-viral activity against HCoV-OC43 and SARS-CoV-2, with EC<sub>50</sub> values of  $0.16 \pm 0.01 \mu$ M and  $0.17 \pm 0.07 \mu$ M, respectively. Thus, a novel SARS-CoV-2 inhibitor targeting the N protein was discovered and its anti-viral activity in vitro was validated. The results may contribute to the development of promising therapeutic agents for COVID-19

## More information: Yang Liu et al,

1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one inhibits SARS-CoV-2 by targeting the nucleocapsid protein, *Acta Materia Medica* (2023). DOI: 10.15212/AMM-2023-0021

Provided by Compuscript Ltd

Citation: Newly-identified compound inhibits SARS-CoV-2 by targeting the nucleocapsid



protein (2023, July 10) retrieved 15 May 2024 from <u>https://phys.org/news/2023-07-newly-identified-compound-inhibits-sars-cov-nucleocapsid.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.